Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04959201 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2024 to Dec 2026
    • Study completion date: Mar 2025 to Mar 2027
    v6
  2. Enrollment target: 60 to 90v5
  3. 2 versions Re-verified since Jul 19, 2022, no change to tracked fieldsv3-v4
  4. Secondary endpoints: details revised at 1 of 9 entriesv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Trial Details
NCT Number NCT04959201
Lead Sponsor China Medical University Hospital
Collaborators: Ministry of Science and Technology, Taiwan
Conditions
(from sponsor)		 Schizophrenia
Related terms Schizophrenia
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov